

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Neurology</b>				
Neurology	Histone deacetylase 2 (HDAC2)	<p>Mouse studies suggest inhibiting HDAC2 in the brain could help improve cognitive function in neuropsychiatric and neurodegenerative diseases. Mice with forebrain-specific disruption of <i>Hdac2</i> showed better performance on tests of conditioned associative learning and had higher hippocampal synaptic function than wild-type controls. Next steps include identifying and testing brain-penetrant, selective inhibitors of HDAC2 in murine models for cognitive dysfunction. Acetylon Pharmaceuticals Inc. has an inhibitor of HDAC1 and HDAC2 in preclinical development for thalassemia and sickle cell disease.</p> <p><b>SciBX 6(20); doi:10.1038/scibx.2013.495</b>  <b>Published online May 23, 2013</b></p>	Unpatented; licensing status not applicable	<p>Morris, M.J. <i>et al. J. Neurosci.</i>; published online April 10, 2013; doi:10.1523/JNEUROSCI.1001-12.2013  <b>Contact:</b> Lisa M. Monteggia, The University of Texas Southwestern Medical Center, Dallas, Texas                      e-mail: <a href="mailto:lisa.monteggia@utsouthwestern.edu">lisa.monteggia@utsouthwestern.edu</a></p>